Literature DB >> 6415733

Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo.

T Aaes-Jørgensen, L Kirk, E Petersen, P Danneskiold-Samsøe, A Jørgensen.   

Abstract

Cis(Z)-clopenthixol decanoate in Viscoleo (Sordinol Depot, Cisordinol Depot, Clopixol Inj.) was given intramuscularly to nine schizophrenic patients with dosage intervals of 1 or 2 weeks. Serum concentrations of the two geometric isomers of clopenthixol and its N-dealkyl metabolite were recorded in two successive dosage intervals. Significant correlations were found for dose vs area under the serum concentration curve and vs serum concentrations measured on individual days. The last mentioned concentrations are good measures of the area under the serum concentration curve, which expresses the drug load of the patient. The serum concentration curves in two successive dosage intervals were very similar. Maximum serum concentration was seen 5-7 days after injection and the mean maximum/minimum fluctuation was 1.6 with the 2-week dosage interval. The finding of very low amounts of the trans(E)-isomers of clopenthixol and the N-dealkyl-metabolite shows that isomerization of the cis(Z)-compounds into the corresponding trans(E)-isomers does not take place within the organism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415733     DOI: 10.1007/BF00439276

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

2.  High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.

Authors:  N Bjørndal; M Bjerre; J Gerlach; P Kristjansen; G Magelund; I H Oestrich; J Waehrens
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

3.  Specific high-performance liquid chromatographic method for estimation of the cis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metabolite.

Authors:  T Aaes-Jørgensen
Journal:  J Chromatogr       Date:  1980-08-08

4.  Low plasma levels of CPZ in patients chronically treated with neuroleptics.

Authors:  R J Wyatt; L Lasagna
Journal:  Commun Psychopharmacol       Date:  1978

5.  Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients.

Authors:  J A Stauning; L Kirk; A Jøorgensen
Journal:  Psychopharmacology (Berl)       Date:  1979-09       Impact factor: 4.530

6.  Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol.

Authors:  T Aaes-Jørgensen; A Gravem; A Jørgensen
Journal:  Acta Psychiatr Scand Suppl       Date:  1981

7.  Pharmacokinetic studies on clopenthixol decanoate; a comparison with clopenthixol in dogs and rats.

Authors:  T Aaes-Jorgensen; K F Overo; K P Bogeso; A Jorgensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-08

8.  Clinical pharmacokinetic studies of perphenazine.

Authors:  C Eggert Hansen; T Rosted Christensen; J Elley; L Bolvig Hansen; P Kragh-Sorensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

9.  Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.

Authors:  L B Hansen; N E Larsen
Journal:  Psychopharmacology (Berl)       Date:  1977-07-18       Impact factor: 4.530

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more
  9 in total

1.  Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.

Authors:  A Viala; B Ba; A Durand; F Gouezo; N Hou; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 2.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

3.  Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate.

Authors:  B Szukalski; B Lipska; L Welbel; K Nurowska
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state.

Authors:  A Jørgensen; T Aaes-Jørgensen; A Gravem; K F Amthor; S J Dencker; I Rosell; P C Baastrup; J Buckhave; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 5.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.

Authors:  A Viala; N Hou; B Ba; A Durand; H Dufour; N D'Agostino; C Berda; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

8.  Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo.

Authors:  A Amdisen; T Aaes-Jørgensen; N J Thomsen; V T Madsen; M S Nielsen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Zuclopenthixol levels in serum and breast milk.

Authors:  T Aaes-Jørgensen; F Bjørndal; U Bartels
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.